Key statistics
On Friday, Novo Nordisk A/S (NOV:DUS) closed at 100.78, 15.24% above the 52 week low of 87.45 set on Dec 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 97.90 |
---|---|
High | 100.78 |
Low | 97.43 |
Bid | -- |
Offer | -- |
Previous close | 100.78 |
Average volume | 4.37k |
---|---|
Shares outstanding | 3.39bn |
Free float | 2.11bn |
P/E (TTM) | 35.42 |
Market cap | 2.55tn DKK |
EPS (TTM) | 21.20 DKK |
Annual div (ADY) | 1.33 EUR |
---|---|
Annual div yield (ADY) | 1.32% |
Div ex-date | Aug 15 2024 |
Div pay-date | Aug 19 2024 |
Data delayed at least 15 minutes, as of Nov 22 2024 18:30 GMT.
More ▼
Announcements
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
- Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024
- Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
- Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial
- Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
- Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
- Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
More ▼